English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/123465
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Multitarget drug discovery for Alzheimer's disease: Triazinones as BACE-1 and GSK-3ß inhibitors

AuthorsPérez, Daniel I.; Pérez Castillo, Ana ; Martínez, Ana ; Bolognesi, Maria Laura; Cavalli, Andrea
Issue Date2015
CitationAngewandte Chemie International Edition 54(5): 1578-1582 (2015)
AbstractCumulative evidence strongly supports that the amyloid and tau hypotheses are not mutually exclusive, but concomitantly contribute to neurodegeneration in Alzheimer's disease (AD). Thus, the development of multitarget drugs which are involved in both pathways might represent a promising therapeutic strategy. Accordingly, reported here in is the discovery of 6-amino-4-phenyl-3, 4-dihydro-1, 3, 5-triazin-2(1H)-ones as the first class of molecules able to simultaneously modulate BACE-1 and GSK-3ß. Notably, one triazinone showed well-balanced in vitro potencies against the two enzymes (IC50 of (18.03 ±0.01) ¿M and (14.67±0.78)¿UM for BACE-1 and GSK-3ß, respectively). In cell-based assays, it displayed effective neuroprotective and neurogenic activities and no neurotoxicity. It also showed good brain permeability in a preliminary pharmacokinetic assessment in mice. Overall, triazinones might represent a promising starting point towards high quality lead compounds with an AD-modifying potential.
Descriptionet al.
Identifiersdoi: 10.1002/anie.201410456
issn: 1433-7851
e-issn: 1521-3773
Appears in Collections:(IIBM) Artículos
(CIB) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.